<code id='56F8664795'></code><style id='56F8664795'></style>
    • <acronym id='56F8664795'></acronym>
      <center id='56F8664795'><center id='56F8664795'><tfoot id='56F8664795'></tfoot></center><abbr id='56F8664795'><dir id='56F8664795'><tfoot id='56F8664795'></tfoot><noframes id='56F8664795'>

    • <optgroup id='56F8664795'><strike id='56F8664795'><sup id='56F8664795'></sup></strike><code id='56F8664795'></code></optgroup>
        1. <b id='56F8664795'><label id='56F8664795'><select id='56F8664795'><dt id='56F8664795'><span id='56F8664795'></span></dt></select></label></b><u id='56F8664795'></u>
          <i id='56F8664795'><strike id='56F8664795'><tt id='56F8664795'><pre id='56F8664795'></pre></tt></strike></i>

          entertainment

          entertainment

          author:hotspot    Page View:4233
          STAT

          What if CRISPR isn’t all that commercial? How does the NurOwn story end? And how do you pronounce “Bayer”?

          We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. Live from Boston at the 2023 STAT Summit, we discuss the latest news in the life sciences, including a milestone in genome editing, a twist in the search for ALS treatments, and the polarizing process of saying words in biotech.

          advertisement

          For more on what we cover, here’s the latest from the Summit; here’s where you can find episodes of Color Code; and here’s where you can subscribe to the First Opinion Podcast.

          Be sure to sign up on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.

          And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].

          advertisement

          explore

          In age of alternative facts, a scholarly course on calling out crap
          In age of alternative facts, a scholarly course on calling out crap

          Screenshotviacallingbullshit.orgTiredofalternativefacts,fakenews,andbreathlesshyperbole,twoprofessor

          read more
          JPM 2024 Day 3: Biotech Updates from Verve, Roivant, etc
          JPM 2024 Day 3: Biotech Updates from Verve, Roivant, etc

          InhonorofJPMWeek,you’rereadingaspecialeditionofourbiotechnewsletter,TheReadout.Tostayontopofthelates

          read more
          Hepatitis C has a cure — but many Americans still lack access to it
          Hepatitis C has a cure — but many Americans still lack access to it

          AdobeIn2005,NickVoyleswasdiagnosedwithhepatitisCafterbeingreleasedfromfiveyearsofincarceration.Anurs

          read more

          At JPM, Bristol Myers Squibb CEO tries to soothe investor nerves

          BristolCEOChristopherBoernerBusinessWireviaAPSANFRANCISCO— ChristopherBoernerhasbeentheCEOofBristolM